enGene Holdings Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
6.52
+0.45 (7.50%)
At close: Sep 17, 2025, 4:00 PM EDT
6.52
0.00 (0.00%)
After-hours: Sep 17, 2025, 4:00 PM EDT
enGene Holdings Employees
As of October 31, 2024, enGene Holdings had 57 total employees, including 56 full-time and 1 part-time employees. The number of employees increased by 24 or 72.73% compared to the previous year.
Employees
57
Change (1Y)
24
Growth (1Y)
72.73%
Revenue / Employee
n/a
Profits / Employee
-$1,661,772
Market Cap
325.28M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Oct 31, 2024 | 57 | 24 | 72.73% |
| Oct 31, 2023 | 33 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ENGN News
- 6 days ago - enGene Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 6 days ago - EnGene Holdings Inc. (ENGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 14 days ago - enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort - Business Wire
- 21 days ago - enGene to Participate in Upcoming Investor Conferences - Business Wire
- 6 weeks ago - enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - enGene Announces Board and Leadership Appointments to Support Commercial Readiness - Business Wire
- 3 months ago - FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer - Business Wire
- 3 months ago - enGene Holdings: Looking For An End To The 2025 Decline (Downgrade) - Seeking Alpha